TrialJournal of neurology2022

Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update.

Thomas H Brannagan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.